Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.46 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891321 | 1.00 | SIGMAR1 (0.58) | SIGMAR1APAF1ACP3MEN1KMT2A | |
| SCHEMBL4891317 | 1.00 | SIGMAR1 (0.58) | SIGMAR1APAF1ACP3MEN1KMT2A | |
| SCHEMBL21193183 | 1.00 | SIGMAR1 (0.58) | SIGMAR1APAF1ACP3MEN1KMT2A | |
| SCHEMBL4884775 | 1.00 | SIGMAR1 (0.58) | SIGMAR1APAF1ACP3MEN1KMT2A | |
| SCHEMBL4884771 | 1.00 | SIGMAR1 (0.58) | SIGMAR1APAF1ACP3MEN1KMT2A | |
| SCHEMBL4887049 | 0.85 | FFAR1 (0.47) | APAF1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4889916 | 0.85 | FFAR1 (0.47) | APAF1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4887058 | 0.85 | FFAR1 (0.47) | APAF1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4881853 | 0.84 | SIGMAR1 (0.49) | SIGMAR1APAF1ACP3MEN1KMT2A | |
| SCHEMBL20577929 | 0.84 | SIGMAR1 (0.53) | SIGMAR1APAF1ACP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| EP-3746075-A1 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-12-09 | — | — | EP | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| EP-1493819-B1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | UBE INDUSTRIES (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-7449325-B2 | Process for enzymatically producing either optically active N-substituted β-amino acids or esters thereof or optically active N-substituted 2-homopipecolic acids or esters thereof | UBE INDUSTRIES, LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050170473-A1 | Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester | UBE INDUSTRIES, LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1493819-A1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | Ube Industries, Ltd. (JP) | 2005-01-05 | — | — | EP | disclosed |
| EP-0736031-B1 | IMPROVEMENTS IN OR RELATING TO CHIRAL SYNTHESES | OXFORD ASYMMETRY INTERNATIONAL (GB) | 2000-05-03 | — | — | EP | disclosed |
| US-6037498-A | Chiral syntheses | OXFORD ASYMMETRY INTERNATIONAL PLC (GB) | 2000-03-14 | — | — | US | disclosed |
| EP-0736031-A1 | IMPROVEMENTS IN OR RELATING TO CHIRAL SYNTHESES | OXFORD ASYMMETRY LIMITED (GB) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995018134-A1 | IMPROVEMENTS IN OR RELATING TO CHIRAL SYNTHESES | OXFORD ASYMMETRY LIMITED (GB) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050170473-A1 | Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester | CYP8B1, SRR, HM13 | SIGMAR1 1339/4885APAF1 1801/4885ACP3 2320/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | SIGMAR1 2011/4885APAF1 2038/4885ACP3 2202/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | SIGMAR1 2335/4885APAF1 1928/4885ACP3 2889/4885 |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | SIGMAR1 2011/4885APAF1 2038/4885ACP3 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.